Cutaneous abscess: Difference between revisions
(2 intermediate revisions by 2 users not shown) | |||
Line 245: | Line 245: | ||
===Natural History=== | ===Natural History=== | ||
If cutaneous abscess left untreated it may drain spontaneously. However, in severe cases it may cause systemic spread and result in [[sepsis]].<ref name="pmid6444142">{{cite journal |vauthors=Llera JL, Levy RC, Staneck JL |title=Cutaneous abscesses: natural history and management in an outpatient facility |journal=J Emerg Med |volume=1 |issue=6 |pages=489–93 |year=1984 |pmid=6444142 |doi= |url=}}</ref> | If cutaneous abscess left untreated it may drain spontaneously. However, in severe cases it may cause systemic spread and result in [[sepsis]].<ref name="pmid6444142">{{cite journal |vauthors=Llera JL, Levy RC, Staneck JL |title=Cutaneous abscesses: natural history and management in an outpatient facility |journal=J Emerg Med |volume=1 |issue=6 |pages=489–93 |year=1984 |pmid=6444142 |doi= |url=}}</ref> | ||
Recurrence may occur in 20% of patients<ref name="pmid33197926">{{cite journal| author=Vella V, Galgani I, Polito L, Arora AK, Creech CB, David MZ | display-authors=etal| title=Staphylococcus aureus skin and soft tissue infection recurrence rates in outpatients: a retrospective database study at three US medical centers. | journal=Clin Infect Dis | year= 2020 | volume= | issue= | pages= | pmid=33197926 | doi=10.1093/cid/ciaa1717 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=33197926 }} </ref>. | |||
===Complications=== | ===Complications=== | ||
A wide range of complications are possible in the course of skin abscess including: [[Bacteremia]], [[endocarditis]], [[osteomyelitis]], metastatic infection, [[sepsis]], and [[toxic shock syndrome]].<ref name="pmid27434444">{{cite journal |vauthors=Raff AB, Kroshinsky D |title=Cellulitis: A Review |journal=JAMA |volume=316 |issue=3 |pages=325–37 |year=2016 |pmid=27434444 |doi=10.1001/jama.2016.8825 |url=}}</ref> | A wide range of complications are possible in the course of skin abscess including: [[Bacteremia]], [[endocarditis]], [[osteomyelitis]], metastatic infection, [[sepsis]], and [[toxic shock syndrome]].<ref name="pmid27434444">{{cite journal |vauthors=Raff AB, Kroshinsky D |title=Cellulitis: A Review |journal=JAMA |volume=316 |issue=3 |pages=325–37 |year=2016 |pmid=27434444 |doi=10.1001/jama.2016.8825 |url=}}</ref> | ||
Line 309: | Line 312: | ||
Avoid sharing personal hygiene items (razors, towels and brushes).<ref name="pmid21208910">{{cite journal |vauthors=Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF |title=Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children |journal=Clin. Infect. Dis. |volume=52 |issue=3 |pages=e18–55 |year=2011 |pmid=21208910 |doi=10.1093/cid/ciq146 |url=}}</ref> | Avoid sharing personal hygiene items (razors, towels and brushes).<ref name="pmid21208910">{{cite journal |vauthors=Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF |title=Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children |journal=Clin. Infect. Dis. |volume=52 |issue=3 |pages=e18–55 |year=2011 |pmid=21208910 |doi=10.1093/cid/ciq146 |url=}}</ref> | ||
===Secondary prevention=== | ===Secondary prevention=== | ||
Decolonization of the index patient and of household contacts may be considered for patients with recurrent infections by using:<ref name="pmid21208910">{{cite journal |vauthors=Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF |title=Clinical practice guidelines by the infectious diseases society of | Decolonization of the index patient and of household contacts may be considered for patients with recurrent infections by using:<ref name="pmid21208910">{{cite journal |vauthors=Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF |title=Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children |journal=Clin. Infect. Dis. |volume=52 |issue=3 |pages=e18–55 |year=2011 |pmid=21208910 |doi=10.1093/cid/ciq146 |url=}}</ref> | ||
*Apply 2% [[mupirocin]] ointment in nasal flares by using sterile applicators twice a day for 5 days. | * Mupirocin | ||
*Apply 4% [[Chlorhexidine gluconate]] solution for all body parts except for face, mucus membranes and open wounds followed by rinsing daily for 5 days. | **Apply 2% [[mupirocin]] ointment in nasal flares by using sterile applicators twice a day for 5 days. | ||
**Topical [[mupirocin]] applied to the nares.<ref name="pmid18843708">{{cite journal |author=van Rijen M, Bonten M, Wenzel R, Kluytmans J |title=Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers |journal=Cochrane Database Syst Rev |volume= |issue=4 |pages=CD006216 |year=2008 |pmid=18843708 |doi=10.1002/14651858.CD006216.pub2 |url=}}</ref> In this [[randomized controlled trial]], patients used nasal mupirocin twice daily 5 days a month for 1 year.<ref name=Raz1996>{{cite journal | author = Raz R, Miron D, Colodner R, Staler Z, Samara Z, Keness Y | title = A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection. | journal = Arch Intern Med | volume = 156 | issue = 10 | pages = 1109-12 | year = 1996 | id = PMID 8638999}}</ref> The does is about 1 centimeter of ointment on a swab applied to each nares.<ref name="pmid10348762">{{cite journal |author=Harbarth S, Dharan S, Liassine N, Herrault P, Auckenthaler R, Pittet D |title=Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus |journal=Antimicrob. Agents Chemother. |volume=43 |issue=6 |pages=1412–6 |year=1999 |month=June |pmid=10348762 |pmc=89288 |doi= |url=http://aac.asm.org/cgi/pmidlookup?view=long&pmid=10348762 |issn=}}</ref> | |||
* Chlorhexidine | |||
**Apply 4% [[Chlorhexidine gluconate]] solution for all body parts except for face, mucus membranes and open wounds followed by rinsing daily for 5 days. | |||
A more intensive regimen, although not used in this setting, has been described<ref name="pmid30763195">{{cite journal| author=Huang SS, Singh R, McKinnell JA, Park S, Gombosev A, Eells SJ et al.| title=Decolonization to Reduce Postdischarge Infection Risk among MRSA Carriers. | journal=N Engl J Med | year= 2019 | volume= 380 | issue= 7 | pages= 638-650 | pmid=30763195 | doi=10.1056/NEJMoa1716771 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30763195 }} </ref>. | A more intensive regimen, although not used in this setting, has been described<ref name="pmid30763195">{{cite journal| author=Huang SS, Singh R, McKinnell JA, Park S, Gombosev A, Eells SJ et al.| title=Decolonization to Reduce Postdischarge Infection Risk among MRSA Carriers. | journal=N Engl J Med | year= 2019 | volume= 380 | issue= 7 | pages= 638-650 | pmid=30763195 | doi=10.1056/NEJMoa1716771 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30763195 }} </ref>. | ||
To prevent recurrent infections due to ''[[Staphylococcus aureus]]'', consider the following measures: | |||
**[[Chlorhexidine]] baths,<ref name=Watanakunakorn>{{cite journal | author = Watanakunakorn C, Axelson C, Bota B, Stahl C | title = Mupirocin ointment with and without chlorhexidine baths in the eradication of Staphylococcus aureus nasal carriage in nursing home residents. | journal = Am J Infect Control | volume = 23 | issue = 5 | pages = 306-9 | year = 1995 | id = PMID 8585642}}</ref> in a [[randomized controlled trial]], nasal recolonization with S. aureus occurred at 12 weeks in 24% of nursing home residents receiving mupirocin ointment alone (6/25) and in 15% of residents receiving mupirocin ointment plus chlorhexidine baths daily for the first three days of mupirocin treatment (4/27). Although these results did not reach [[statistical significance]], the baths are easy to do. | |||
==References== | ==References== | ||
Line 318: | Line 326: | ||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
[[Category:General surgery]][[Category:Emergency medicine]] | [[Category:General surgery]] | ||
[[Category:Emergency medicine]] | |||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
[[Category:Surgery]] | [[Category:Surgery]] |
Latest revision as of 08:20, 14 December 2020
Cutaneous abscess | |
Abscess |
WikiDoc Resources for Cutaneous abscess |
Articles |
---|
Most recent articles on Cutaneous abscess Most cited articles on Cutaneous abscess |
Media |
Powerpoint slides on Cutaneous abscess |
Evidence Based Medicine |
Cochrane Collaboration on Cutaneous abscess |
Clinical Trials |
Ongoing Trials on Cutaneous abscess at Clinical Trials.gov Trial results on Cutaneous abscess Clinical Trials on Cutaneous abscess at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Cutaneous abscess NICE Guidance on Cutaneous abscess
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Cutaneous abscess Discussion groups on Cutaneous abscess Patient Handouts on Cutaneous abscess Directions to Hospitals Treating Cutaneous abscess Risk calculators and risk factors for Cutaneous abscess
|
Healthcare Provider Resources |
Causes & Risk Factors for Cutaneous abscess |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
For patient information click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Seyedmahdi Pahlavani, M.D. [2]
Synonyms and keywords:Skin abscess
To return to abscess main page, click here.
Overview
Cutaneous abscess is defined as a collection of pus in the dermis or subcutaneous tissue and appears as a swollen, red, tender, and fluctuant mass, often with surrounding cellulitis and may occur in any part of the body. Although, there is a rare type of sterile skin abscess that is secondary to injection mostly in diabetic patients who use insulin. diagnosis is clinical and consist of a painful, tender, indurated, and usually erythematous nodule or mass that is varying in size. Systemic sign and symptoms are rare except for sever and multiple abscess especially in immunocompromised patients. Treatment is, incision and drainage associated with antibiotics.
Historical perspective
Alexander Ogston, a scottish surgeon first described the pyogenic abscess in the late 19th century.[1]
Classification
Cutaneous abscess may be classified as sterile abscess and infectious abscess.
- Sterile abscesses are mainly seen in diabetic patients secondary to insulin injection.
- Infectious abscesses which are mostly due to staphylococcus aureus infection.
Pathophysiology
Abscess is usually caused by staphylococcus aureus bacterial infection in an injured skin. Staphylococcus aureus could form abscess by secretion of several enzymes and toxins. In a reaction to these bacterial substances, assembled white blood cells in this tissue produces anti-bacterial anti-bodies that help in bacterial elimination. However, these cells cause damage to the soft tissue contributing in the abscess formation.[2]
Pathogenesis
Skin serves as a barrier from pathogen entry. Breech in the skin surface allow the pathogen entry to cause local inflammation. Polymorphonuclear cells (PMNs) are the first and the most important responding cells in abscess formation.[3] Neutrophils, are responsible for phagocytosis. Once the pathogen is opsonized by complement system, it will be recognized by neutrophils and the phagocytosis process will begin. After phagocytosis the bactricidal process will begin by producing superoxide radicals and other reactive oxygen species (ROS).[4]
Genetic factors
PMNs are the most important cellular defense. Genetic disorders that negatively affect PMN function may predispose persons to recurrent cutaneous abscess formation. For example, chronic granulomatous disease, which is a genetic disorder characterized by the inability of PMNs and other phagocytes to produce superoxide, often presents with severe and recurrent S. aureus infections.[5]
Causes
Common causes
- S. aureus (either methicillin-susceptible or methicillin-resistant S. aureus) is counting for 75% of cases.[6]
- Mixed flora (including S. aureus together with S. pyogenes and gram-negative bacilli with anaerobes)[7][8]
- Anaerobes, mostly seen in injecting drug users.[7]
Less common causes
Nontuberculous mycobacteria, blastomycosis, nocardiosis, and cryptococcosis.[7]
Differentiating cutaneous abscess from other Diseases
- Cutaneous abscess must be differentiated from other causes of lower limb edema like chronic venous insufficiency, acute deep venous thrombosis, lipedema, myxedema, lymphatic filariasis and causes of generalized edema.
Diseases | Symptoms | Signs | Gold standard Investigation to diagnose | ||||||
---|---|---|---|---|---|---|---|---|---|
History | Onset | Pain | Fever | Laterality | Scrotal swelling | Symptoms of primary disease | |||
(Cellulitis-erysipelas-skin abscess) | Acute | + | + | Unilateral | - | - |
|
| |
Lymphatic filariasis |
|
Chronic | + | + | Bilateral | + | - |
|
Preparing blood smears
By the ultrasound, the following findings can be observed:
|
Chronic venous insufficiency |
|
Chronic | + | - | Bilateral | +
(If congenial) |
- |
| |
Acute deep venous thrombosis | Acute | + | - | Unilateral | - | May be associated with primary disease mandates recumbency for long duration |
|
| |
Lipedema |
|
Chronic | + | - | Bilateral | - | - |
|
|
Myxedema |
|
Chronic | + | - | Bilateral | - | + | ||
Other causes of generalized edema |
|
Chronic | - | - | Bilateral | - | + |
|
Disease | Clinical features |
---|---|
Folliculitis | Hair follicle inflammation, presents as pruritic rash or pustule.[16][17] |
Suppurative hydradenitis | Inflammation in intertriginous areas (axillae, inguinal area, inner thighs, perianal and perineal areas, mammary,..)
Presents as painful inflamed nodule, sinus tract and commedons. Associated with systemic symptoms. Needs surgical debridement and systemic antibiotic.[18] |
Epidermoid cyst | Cyst or nodule presents with central punctum. May be secondarily infected.[19] |
Nodular lymphangitis | Subcutaneous swelling along with lymphatics. mostly due to Sporothrix schenckii.[20] |
Myiasis | Enlarging nodule secondary to insect bite and due to penetration of fly larvae into subdermal tissue. caused by Dermatobia hominis, the botfly and Cordylobia anthropophaga, the tumbu fly.[21] |
Epidemiology and Demographics
- It is estimated that 4% of children experience the cutaneous abscess.[22]
A national emergency department visit survey from 1996 to 2005 showed:
- Emergency department visits for abscesses more than doubled over the 10-year study period (1.2 million in 1996 to 3.28 million in 2005).
Gender
Men and women are affected equally.
Age
It is more common among adults age 19 to 45 years.
Risk Factors
Risk factors for developing cutaneous abscess include:[23][24]
- Skin barrier disruption due to trauma (such as abrasion, penetrating wound, pressure ulcer, venous leg ulcer, insect bite, injection drug use)
- Skin inflammation (such as eczema, radiation therapy)
- Edema due to impaired lymphatic drainage
- Edema due to venous insufficiency
- Obesity
- Immunosuppression (such as diabetes or HIV infection)
- Breaks in the skin between the toes (toe web intertrigo); these may be clinically inapparent
- Preexisting skin infection (such as tinea pedis, impetigo, varicella)
- Hemodialysis
Natural History, Complications and Prognosis
Natural History
If cutaneous abscess left untreated it may drain spontaneously. However, in severe cases it may cause systemic spread and result in sepsis.[25]
Recurrence may occur in 20% of patients[26].
Complications
A wide range of complications are possible in the course of skin abscess including: Bacteremia, endocarditis, osteomyelitis, metastatic infection, sepsis, and toxic shock syndrome.[9]
Prognosis
Depending on the extent of the disease, the prognosis may vary. However, the prognosis is generally regarded as good.
Patients who require hospitalization for ICU admission, operating room surgical intervention, or death have one of the following six risk factors upon presentation[27]:
- abnormal cross-sectional imaging result ("air or gas, abscess or fluid collection, osteomyelitis, or suspicion of osteomyelitis")
- systemic inflammatory response syndrome
- previous infection at the same location
- infection involving the hand * diabetes* age >65 years
Diagnosis
History and symptoms
History
A detailed history must be taken from all patients. Specific area of focus when obtaining a history from the patient include:
- Recent trauma
- Recent weight change
- Recent immunosuppresive drugs
- Underlying comorbidities (lymphedema, malignancy, neutropenia, immunodeficiency, splenectomy, diabetes)
Symptoms
The hallmark of the cutaneous abscess is painful, tender, indurated, and usually erythematous nodule.
Physical examination
Appearance of the Patient
Patients are usually well appearing.
Vital signs
Vital signs are within normal limits unless there is complication.
Skin
Indurated, tender and erythematous nodule with signs of local inflammation is the presenting feature.
Laboratory findings
Leukocytosis and increased level of acute phase reactants (ESR, CRP) are the most common laboratory findings.
Treatment
Treatment is based on incision and drainage and sometimes antibiotic therapy is required. Cure rates with drainage alone are about 85% or higher.[28][29]
Patients who require hospitalization for ICU admission, operating room surgical intervention, or death have one of the following six risk factors upon presentation[27]:* abnormal cross-sectional imaging result* systemic inflammatory response syndrome* previous infection at the same location* infection involving the hand * diabetes* age >65 years
Medical therapy
Antibiotic therapy is indicated in some circumstances that include and the duration based on severity and clinical response varies between 3 to 7 days:[30][31][32]
- Single abscess ≥2 cm
- Multiple lesions
- Extensive surrounding cellulitis
- Associated immunosuppression or other comorbidities
- Systemic signs of toxicity (fever >100.5°F/38°C, hypotension, or sustained tachycardia)
- Inadequate clinical response to incision and drainage alone
- Presence of an indwelling medical device (such as prosthetic joint, vascular graft, or pacemaker)
- High risk for transmission of S. aureus to others (such as in athletes, military personnel)
Antibiotic therapy[33][34][29]
- Preferred regimen: Trimethoprim-sulfamethoxazole one or two double strength doses (160 mg of trimethoprim and 800 mg of sulfamethoxazole) PO twice daily
- Alternative regimen (1): Clindamycin 300-450 mg PO three to four times daily
- Alternative regimen (2): Doxycycline 100 mg PO twice daily
- Alternative regimen (3): Minocycline 200 mg PO once, then 100 mg PO twice daily
- Alternative regimen (4): Linezolid 600 mg PO twice daily
- Alternative regimen (5): Tedizolid 200 mg PO once daily
Surgery
Incision and drainage is the preferred method of treatment for cutaneous abscesses.[35] The following video, shows this procedure.{{#ev:youtube|MwgNdrA18fM}}
Prevention
Primary prevention
Avoid sharing personal hygiene items (razors, towels and brushes).[30]
Secondary prevention
Decolonization of the index patient and of household contacts may be considered for patients with recurrent infections by using:[30]
- Mupirocin
- Apply 2% mupirocin ointment in nasal flares by using sterile applicators twice a day for 5 days.
- Topical mupirocin applied to the nares.[36] In this randomized controlled trial, patients used nasal mupirocin twice daily 5 days a month for 1 year.[37] The does is about 1 centimeter of ointment on a swab applied to each nares.[38]
- Chlorhexidine
- Apply 4% Chlorhexidine gluconate solution for all body parts except for face, mucus membranes and open wounds followed by rinsing daily for 5 days.
A more intensive regimen, although not used in this setting, has been described[39]. To prevent recurrent infections due to Staphylococcus aureus, consider the following measures:
- Chlorhexidine baths,[40] in a randomized controlled trial, nasal recolonization with S. aureus occurred at 12 weeks in 24% of nursing home residents receiving mupirocin ointment alone (6/25) and in 15% of residents receiving mupirocin ointment plus chlorhexidine baths daily for the first three days of mupirocin treatment (4/27). Although these results did not reach statistical significance, the baths are easy to do.
References
- ↑ "Classics in infectious diseases. "On abscesses". Alexander Ogston (1844-1929)". Rev. Infect. Dis. 6 (1): 122–8. 1984. PMID 6369479.
- ↑ Kobayashi SD, Malachowa N, DeLeo FR (2015). "Pathogenesis of Staphylococcus aureus abscesses". Am J Pathol. 185 (6): 1518–27. doi:10.1016/j.ajpath.2014.11.030. PMC 4450319. PMID 25749135.
- ↑ Kolaczkowska E, Kubes P (2013). "Neutrophil recruitment and function in health and inflammation". Nat. Rev. Immunol. 13 (3): 159–75. doi:10.1038/nri3399. PMID 23435331.
- ↑ Quinn MT, Gauss KA (2004). "Structure and regulation of the neutrophil respiratory burst oxidase: comparison with nonphagocyte oxidases". J. Leukoc. Biol. 76 (4): 760–81. doi:10.1189/jlb.0404216. PMID 15240752.
- ↑ Bieluch VM, Tally FP (1983). "Pathophysiology of abscess formation". Clin Obstet Gynaecol. 10 (1): 93–103. PMID 6872404.
- ↑ 6.0 6.1 Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC (2014). "Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America". Clin. Infect. Dis. 59 (2): 147–59. doi:10.1093/cid/ciu296. PMID 24947530.
- ↑ 7.0 7.1 7.2 Summanen PH, Talan DA, Strong C, McTeague M, Bennion R, Thompson JE, Väisänen ML, Moran G, Winer M, Finegold SM (1995). "Bacteriology of skin and soft-tissue infections: comparison of infections in intravenous drug users and individuals with no history of intravenous drug use". Clin. Infect. Dis. 20 Suppl 2: S279–82. PMID 7548575.
- ↑ Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, Talan DA (2006). "Methicillin-resistant S. aureus infections among patients in the emergency department". N. Engl. J. Med. 355 (7): 666–74. doi:10.1056/NEJMoa055356. PMID 16914702.
- ↑ 9.0 9.1 Raff AB, Kroshinsky D (2016). "Cellulitis: A Review". JAMA. 316 (3): 325–37. doi:10.1001/jama.2016.8825. PMID 27434444.
- ↑ Woo PC, Lum PN, Wong SS, Cheng VC, Yuen KY (2000). "Cellulitis complicating lymphoedema". Eur J Clin Microbiol Infect Dis. 19 (4): 294–7. PMID 10834819.
- ↑ Leppard BJ, Seal DV, Colman G, Hallas G (1985). "The value of bacteriology and serology in the diagnosis of cellulitis and erysipelas". Br J Dermatol. 112 (5): 559–67. PMID 4005155.
- ↑ Goodacre S, Sutton AJ, Sampson FC (2005). "Meta-analysis: The value of clinical assessment in the diagnosis of deep venous thrombosis". Ann Intern Med. 143 (2): 129–39. PMID 16027455. Review in: ACP J Club. 2006 Mar-Apr;144(2):46-7 Review in: Evid Based Med. 2006 Apr;11(2):56
- ↑ Child AH, Gordon KD, Sharpe P, Brice G, Ostergaard P, Jeffery S; et al. (2010). "Lipedema: an inherited condition". Am J Med Genet A. 152A (4): 970–6. doi:10.1002/ajmg.a.33313. PMID 20358611.
- ↑ Trayes KP, Studdiford JS, Pickle S, Tully AS (2013). "Edema: diagnosis and management". Am Fam Physician. 88 (2): 102–10. PMID 23939641.
- ↑ Dimakakos PB, Stefanopoulos T, Antoniades P, Antoniou A, Gouliamos A, Rizos D (1997). "MRI and ultrasonographic findings in the investigation of lymphedema and lipedema". Int Surg. 82 (4): 411–6. PMID 9412843.
- ↑ Luelmo-Aguilar J, Santandreu MS (2004). "Folliculitis: recognition and management". Am J Clin Dermatol. 5 (5): 301–10. PMID 15554731.
- ↑ Laureano AC, Schwartz RA, Cohen PJ (2014). "Facial bacterial infections: folliculitis". Clin. Dermatol. 32 (6): 711–4. doi:10.1016/j.clindermatol.2014.02.009. PMID 25441463.
- ↑ Revuz J (2009). "Hidradenitis suppurativa". J Eur Acad Dermatol Venereol. 23 (9): 985–98. doi:10.1111/j.1468-3083.2009.03356.x. PMID 19682181.
- ↑ Zuber TJ (2002). "Minimal excision technique for epidermoid (sebaceous) cysts". Am Fam Physician. 65 (7): 1409–12, 1417–8, 1420. PMID 11996426.
- ↑ Kostman JR, DiNubile MJ (1993). "Nodular lymphangitis: a distinctive but often unrecognized syndrome". Ann. Intern. Med. 118 (11): 883–8. PMID 8480962.
- ↑ Arosemena R, Booth SA, Su WP (1993). "Cutaneous myiasis". J. Am. Acad. Dermatol. 28 (2 Pt 1): 254–6. PMID 8432924.
- ↑ Holsenback H, Smith L, Stevenson MD (2012). "Cutaneous abscesses in children: epidemiology in the era of methicillin-resistant Staphylococcus aureus in a pediatric emergency department". Pediatr Emerg Care. 28 (7): 684–6. doi:10.1097/PEC.0b013e31825d20e1. PMID 22743746.
- ↑ McNamara DR, Tleyjeh IM, Berbari EF, Lahr BD, Martinez J, Mirzoyev SA, Baddour LM (2007). "A predictive model of recurrent lower extremity cellulitis in a population-based cohort". Arch. Intern. Med. 167 (7): 709–15. doi:10.1001/archinte.167.7.709. PMID 17420430.
- ↑ Gordon RJ, Lowy FD (2005). "Bacterial infections in drug users". N. Engl. J. Med. 353 (18): 1945–54. doi:10.1056/NEJMra042823. PMID 16267325.
- ↑ Llera JL, Levy RC, Staneck JL (1984). "Cutaneous abscesses: natural history and management in an outpatient facility". J Emerg Med. 1 (6): 489–93. PMID 6444142.
- ↑ Vella V, Galgani I, Polito L, Arora AK, Creech CB, David MZ; et al. (2020). "Staphylococcus aureus skin and soft tissue infection recurrence rates in outpatients: a retrospective database study at three US medical centers". Clin Infect Dis. doi:10.1093/cid/ciaa1717. PMID 33197926 Check
|pmid=
value (help). - ↑ 27.0 27.1 Mower WR, Kadera SP, Rodriguez AD, Vanderkraan V, Krishna PK, Chiu E; et al. (2018). "Identification of Clinical Characteristics Associated With High-Level Care Among Patients With Skin and Soft Tissue Infections". Ann Emerg Med. doi:10.1016/j.annemergmed.2018.09.020. PMID 30420232.
- ↑ Rajendran PM, Young D, Maurer T, Chambers H, Perdreau-Remington F, Ro P, Harris H (2007). "Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection". Antimicrob. Agents Chemother. 51 (11): 4044–8. doi:10.1128/AAC.00377-07. PMC 2151464. PMID 17846141.
- ↑ 29.0 29.1 Schmitz GR, Bruner D, Pitotti R, Olderog C, Livengood T, Williams J, Huebner K, Lightfoot J, Ritz B, Bates C, Schmitz M, Mete M, Deye G (2010). "Randomized controlled trial of trimethoprim-sulfamethoxazole for uncomplicated skin abscesses in patients at risk for community-associated methicillin-resistant Staphylococcus aureus infection". Ann Emerg Med. 56 (3): 283–7. doi:10.1016/j.annemergmed.2010.03.002. PMID 20346539.
- ↑ 30.0 30.1 30.2 Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF (2011). "Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children". Clin. Infect. Dis. 52 (3): e18–55. doi:10.1093/cid/ciq146. PMID 21208910.
- ↑ Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC (2014). "Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America". Clin. Infect. Dis. 59 (2): e10–52. doi:10.1093/cid/ciu444. PMID 24973422.
- ↑ Talan DA, Mower WR, Krishnadasan A, Abrahamian FM, Lovecchio F, Karras DJ, Steele MT, Rothman RE, Hoagland R, Moran GJ (2016). "Trimethoprim-Sulfamethoxazole versus Placebo for Uncomplicated Skin Abscess". N. Engl. J. Med. 374 (9): 823–32. doi:10.1056/NEJMoa1507476. PMC 4851110. PMID 26962903.
- ↑ Daum RS, Miller LG, Immergluck L, Fritz S, Creech CB, Young D; et al. (2017). "A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses". N Engl J Med. 376 (26): 2545–2555. doi:10.1056/NEJMoa1607033. PMID 28657870.
- ↑ Talan DA, Krishnadasan A, Gorwitz RJ, Fosheim GE, Limbago B, Albrecht V, Moran GJ (2011). "Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008". Clin. Infect. Dis. 53 (2): 144–9. doi:10.1093/cid/cir308. PMID 21690621.
- ↑ Singer AJ, Talan DA (2014). "Management of skin abscesses in the era of methicillin-resistant Staphylococcus aureus". N. Engl. J. Med. 370 (11): 1039–47. doi:10.1056/NEJMra1212788. PMID 24620867.
- ↑ van Rijen M, Bonten M, Wenzel R, Kluytmans J (2008). "Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers". Cochrane Database Syst Rev (4): CD006216. doi:10.1002/14651858.CD006216.pub2. PMID 18843708.
- ↑ Raz R, Miron D, Colodner R, Staler Z, Samara Z, Keness Y (1996). "A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection". Arch Intern Med. 156 (10): 1109–12. PMID 8638999.
- ↑ Harbarth S, Dharan S, Liassine N, Herrault P, Auckenthaler R, Pittet D (1999). "Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus". Antimicrob. Agents Chemother. 43 (6): 1412–6. PMC 89288. PMID 10348762. Unknown parameter
|month=
ignored (help) - ↑ Huang SS, Singh R, McKinnell JA, Park S, Gombosev A, Eells SJ; et al. (2019). "Decolonization to Reduce Postdischarge Infection Risk among MRSA Carriers". N Engl J Med. 380 (7): 638–650. doi:10.1056/NEJMoa1716771. PMID 30763195.
- ↑ Watanakunakorn C, Axelson C, Bota B, Stahl C (1995). "Mupirocin ointment with and without chlorhexidine baths in the eradication of Staphylococcus aureus nasal carriage in nursing home residents". Am J Infect Control. 23 (5): 306–9. PMID 8585642.